Results of CAV regimen (CCNU, Melphalan, and VP-16) as third-line salvage therapy for Hodgkin's disease

MLA

M. Lazzarino, et al. “Results of CAV Regimen (CCNU, Melphalan, and VP-16) as Third-Line Salvage Therapy for Hodgkin’s Disease.” Annals of Oncology, vol. 5, May 1994, pp. 427–32. EBSCOhost, https://doi.org/10.1093/oxfordjournals.annonc.a058874.

APA

M. Lazzarino, G. Castelli, Cesare Astori, E. Morra, Carlo Bernasconi, A. Canevari, Emilio Paolo Alessandrino, Paolo Bernasconi, Ercole Brusamolino, Ester Orlandi, & Guido Pagnucco. (1994). Results of CAV regimen (CCNU, Melphalan, and VP-16) as third-line salvage therapy for Hodgkin’s disease. Annals of Oncology, 5, 427–432. https://doi.org/10.1093/oxfordjournals.annonc.a058874

Chicago

M. Lazzarino, G. Castelli, Cesare Astori, E. Morra, Carlo Bernasconi, A. Canevari, Emilio Paolo Alessandrino, et al. 1994. “Results of CAV Regimen (CCNU, Melphalan, and VP-16) as Third-Line Salvage Therapy for Hodgkin’s Disease.” Annals of Oncology 5 (May): 427–32. doi:10.1093/oxfordjournals.annonc.a058874.